Fujita H, Mohri H, Kanamori H, Iwamatsu A, Okubo T
First Department of Internal Medicine, Yokohama City University School of Medicine.
Exp Cell Res. 1995 Apr;217(2):484-9. doi: 10.1006/excr.1995.1113.
A 29-kDa monomeric dispase-digestive fragment of human plasma fibronectin has been purified by heparin affinity chromatography. The NH2-terminal sequence was determined as Ala1687-Val-Thr-Thr-Ile-Pro-Ala-Pro. By mass spectrometry the molecular weight was determined to be 30,241.9 with standard deviation of 3.9 amu. Therefore, we defined the C-terminal sequence of the 29-kDa fragment as Arg1957-Lys-Lys-Thr-Gly-Gln-Glu. This indicates that the fragment is composed of 277 amino acids. 125I-fibronectin and the 125I-labeled 29-kDa fragment bound to HL-60 (human acute promyelocytic leukemia) cells in a time-dependent, saturable, and reversible manner. Approximately 120 min was required to reach maximal binding. There were no differences in quantity or rate of binding of labeled fibronectin and 29-kDa fragment at temperatures of 4 degrees, 22 degrees, and 37 degrees C. The number of binding sites per HL-60 cell of fibronectin and the 29-kDa fragment were 140,000 with a Kd of 133 nM and 108,000 with a Kd of 250 nM, respectively. The binding of fibronectin to HL-60 cells was completely inhibited by this fragment, and by the peptides of RGDS and CS1 with IC50s of 3.6, 840, and 670 microM, respectively. Native fibronectin inhibited the direct binding of the 29-kDa fragment to HL-60 cells; however, RGDS peptide, peptide CS1, or two melanoma cell adhesion-promoting domain peptides in this 29-kDa fragment (peptide I; Tyr1906-Val1924, peptide II; Asp1946-Thr1960) did not block this binding. Neither heparitinase nor chondroitinase treatment of cells had any effect on these bindings. These results indicate that the C-terminal cell- and heparin-binding domain of fibronectin mediates HL-60 cell binding by direct interaction independently of RGD, CS1, and melanoma cell adhesion domains in this fragment.
人血浆纤连蛋白的一个29 kDa单体性分散酶消化片段已通过肝素亲和层析法纯化。其氨基末端序列被确定为Ala1687-Val-Thr-Thr-Ile-Pro-Ala-Pro。通过质谱法测定分子量为30,241.9,标准偏差为3.9原子质量单位。因此,我们将该29 kDa片段的羧基末端序列定义为Arg1957-Lys-Lys-Thr-Gly-Gln-Glu。这表明该片段由277个氨基酸组成。125I-纤连蛋白和125I标记的29 kDa片段以时间依赖性、饱和性和可逆性方式与HL-60(人急性早幼粒细胞白血病)细胞结合。达到最大结合大约需要120分钟。在4℃、22℃和37℃温度下,标记的纤连蛋白和29 kDa片段的结合量或结合速率没有差异。纤连蛋白和29 kDa片段在每个HL-60细胞上的结合位点数分别为140,000个,解离常数(Kd)为133 nM和108,000个,Kd为250 nM。纤连蛋白与HL-60细胞的结合被该片段以及RGDS和CS1肽完全抑制,其半数抑制浓度(IC50)分别为3.6、840和670 μM。天然纤连蛋白抑制29 kDa片段与HL-60细胞的直接结合;然而,RGDS肽、CS1肽或该29 kDa片段中的两个黑色素瘤细胞黏附促进结构域肽(肽I;Tyr1906-Val1924,肽II;Asp1946-Thr1960)并未阻断这种结合。用肝素酶或软骨素酶处理细胞对这些结合没有任何影响。这些结果表明,纤连蛋白的羧基末端细胞结合和肝素结合结构域通过直接相互作用介导HL-60细胞结合,独立于该片段中的RGD、CS1和黑色素瘤细胞黏附结构域。